Bowel cancer screening in the UK stops sending automatic invitations at age 74 because, beyond that point, the potential harms of screening begin to outweigh the benefits for most people. That calculation is based on a combination of factors: the rising risk of complications from follow-up procedures, the slower progression of pre-cancerous growths, and the reality that other health conditions become more likely to affect quality and length of life. It’s not that bowel cancer stops being a concern. It’s that routine population-wide screening becomes a less effective tool.
How the NHS Programme Works
The NHS currently offers bowel cancer screening every two years to everyone aged 50 to 74. The test itself is a home stool test (called a FIT, or faecal immunochemical test) that checks for tiny traces of blood. If blood is detected, you’re invited for a colonoscopy to investigate further. At 74, the automatic invitations stop, but this doesn’t mean you’re locked out. Anyone aged 75 or over can request a kit by calling the bowel cancer screening helpline. The difference is that you have to opt in rather than being automatically enrolled.
The Shrinking Window of Benefit
The core purpose of screening is to catch problems early, specifically pre-cancerous polyps that could eventually become cancer. These polyps grow slowly. A small polyp takes roughly 8 to 17 years to progress to cancer, depending on its size, and the smallest ones can take decades. That long timeline is what makes screening so powerful in younger adults: catching a polyp at 55 gives you years of benefit from its removal.
At 75, the math changes. If a new small polyp is found, it may take well over a decade to become dangerous. For many people at that age, other health conditions are more likely to cause serious problems in that same timeframe. Researchers call this “competing causes of death,” and it’s one of the main reasons screening guidelines have an upper limit. In one well-known example from prostate cancer research, 66% of older men with localized cancer died from completely unrelated causes over a 20-year follow-up, compared to 30% who died from the cancer itself. The same principle applies to bowel cancer: finding and treating a slow-growing polyp provides less value when other health risks are more immediate.
Computer modelling studies used by screening bodies, including the US Preventive Services Task Force, consistently show that the “net benefit” of colorectal cancer screening after 75 is small for the general population. That doesn’t mean zero, but it’s small enough that universal screening no longer makes sense as a blanket policy.
Procedural Risks Rise With Age
Screening itself (the home stool test) carries no physical risk. The issue comes when the test finds something and a colonoscopy is needed. A colonoscopy involves sedation, thorough bowel preparation that requires fasting and strong laxatives, and the procedure itself, where a flexible camera is passed through the entire length of the colon.
For people aged 65 to 80, the rate of bowel perforation during colonoscopy is about 0.067%, and the bleeding rate is about 0.12%. Those numbers are low. But for people over 80, the perforation rate jumps to roughly 0.24%, about 2.5 times higher. Bleeding risk also increases. The bowel preparation alone can cause dehydration and electrolyte imbalances, which are more dangerous in older people who may already have kidney problems or heart conditions. These aren’t reasons to never have a colonoscopy after 74, but they are reasons not to funnel an entire population into that pathway without strong evidence of benefit.
Screening Also Becomes Less Effective
The home stool test itself appears to work less well in older adults. Research shows a trend toward reduced sensitivity with age: the test picks up about 85% of cancers in people aged 50 to 59 but closer to 73% in people aged 60 to 69. A large population study found that having a previous screening FIT was associated with a 30% reduction in colorectal cancer risk for people aged 50 to 74, but only a 6% reduction for people 75 and older. Colonoscopy similarly showed a stronger protective effect in younger adults (73% risk reduction for those 50 to 74) compared to a 57% reduction in those 75 and older.
So the tools themselves deliver diminishing returns, even as the risks of using them climb.
When Screening Still Makes Sense After 74
The age cutoff is a population-level guideline, not a personal prescription. For individuals over 74 who are in good overall health, have a life expectancy of 10 years or more, and have never been screened (or haven’t been screened recently), continuing makes more sense. US guidelines for people aged 76 to 85 explicitly recommend that the decision be individualized, taking into account overall health, prior screening history, and personal preference.
If you’ve been screening regularly and your results have consistently been normal, the chance of a dangerous polyp developing and progressing in the years ahead is low. If you’ve never been screened, that’s a different situation, and continuing could catch something that’s been growing undetected.
Screening vs. Diagnostic Testing
One important distinction sometimes gets lost in the age-limit conversation: the cutoff applies to routine screening, meaning testing people who feel fine and have no symptoms. It does not apply to diagnostic investigation. If you’re over 74 and develop symptoms like blood in your stool, a change in bowel habits lasting more than a few weeks, or unexplained weight loss, your GP can and should refer you for investigation regardless of your age. That’s not screening. That’s diagnosing a problem you already have signs of, and there is no age limit on it.
The NHS makes this distinction clearly, and so do international guidelines. Stopping routine screening at 74 does not mean stopping all attention to bowel health. It means shifting from an automated population-wide net to a more targeted, individually considered approach.